Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal
pharmaphorum
JULY 13, 2021
The bulk of Novo Nordisk’s revenues come from its diabetes products, although it also active in the development and sale of drugs for growth disorders, haemophilia and sickle cell disease. In ATTR amyloidosis, transthyretin (TTR) protein misfolds and accumulates as amyloid deposits throughout the body.
Let's personalize your content